MEDIPOST has obtained a US patent related to the treatment method that removes substances that cause Alzheimer’s dementia using a special protein secreted by cord blood stem cells.

The patented technology disintegrates and removes ‘amyloid beta plaque’ known as the substance that causes Alzheimer’s dementia using ‘ICAM-1, the cell adhesion molecule’, a type of protein that interferes the adhesion and movement of infected cells. The technology is applied in the most important process of treating Alzheimer’s dementia.

MEDIPOST explained that the significance of this patent is remarkable concerning the fact that the administration of stem cells derived from cord blood in Alzheimer’s dementia patients display a close function of ‘fundamental treatment’, including the relief of symptoms through the removal of the cause of dementia, ICAM-1 when the administration of the medicine creates various substances that help with the treatment.

The name of the patent is ‘use of ICAM-1 for prevention or treatment of neurological disease’, and this patent can be used on Alzheimer’s dementia, as well as Parkinson’s disease, epilepsy, and mild cognitive impairment.